Patents by Inventor Petra Arndt
Petra Arndt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10258031Abstract: The present invention relates to a recovery assembly for a cooling agent in a cryopreservation device, the recovery assembly comprises a cone-shaped funnel assembly comprising a support for mounting the funnel assembly to an access opening of a container to be at least partially filled with a cooling agent.Type: GrantFiled: August 5, 2014Date of Patent: April 16, 2019Assignee: Sanofi-Aventis Deutschland GMBHInventors: Petra Arndt, Volker Derdau, Verena Siefke-Henzler
-
Publication number: 20180148440Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: July 6, 2017Publication date: May 31, 2018Inventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Michael PODESCHWA, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER, Volker KRAFT, Patrice BELLEVERGUE, Gary MCCORT
-
Publication number: 20170166548Abstract: The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use in pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 8, 2017Publication date: June 15, 2017Inventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Volker KRAFT, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER
-
Publication number: 20170037042Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: April 5, 2016Publication date: February 9, 2017Inventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Michael PODESCHWA, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER, Patrice BELLEVERGUE, Gary MCCORT
-
Patent number: 9550788Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula I and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.Type: GrantFiled: July 24, 2014Date of Patent: January 24, 2017Assignee: SANOFIInventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann
-
Patent number: 9440941Abstract: The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: March 7, 2014Date of Patent: September 13, 2016Assignee: SanofiInventors: Werngard Czechtizky, John Weston, Nils Rackelmann, Volker Kraft, Petra Arndt, Klaus Wirth, Heinz Goegelein, Olaf Ritzeler
-
Publication number: 20160165881Abstract: The present invention relates to a recovery assembly for a cooling agent in a cryopreservation device, the recovery assembly comprises a cone-shaped funnel assembly comprising a support for mounting the funnel assembly to an access opening of a container to be at least partially filled with a cooling agent.Type: ApplicationFiled: August 5, 2014Publication date: June 16, 2016Inventors: Petra Arndt, Volker Derdau, Verena Siefke-Henzler
-
Publication number: 20160158759Abstract: A recovery assembly for a cryopreservation device is presented having a support for mounting the recovery assembly to an access opening of a container to be at least partially filled with the cooling agent, and at least one flow channel to form at least one protective gas stream to reduce escapement of the cooling agent from the container.Type: ApplicationFiled: August 5, 2014Publication date: June 9, 2016Inventors: Volker Derdau, Andreas Wolf, Petra Arndt, Verena Siefke-Henzler, Christoph Dette, Ulrike Milbert
-
Publication number: 20160016928Abstract: The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 7, 2014Publication date: January 21, 2016Applicant: SANOFIInventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Volker KRAFT, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER
-
Publication number: 20150087648Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: November 10, 2014Publication date: March 26, 2015Inventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Michael PODESCHWA, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER, Volker KRAFT, Patrice BELLEVERGUE, Gary McCORT
-
Patent number: 8912224Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: September 12, 2011Date of Patent: December 16, 2014Assignee: SanofiInventors: Werngard Czechtizky, John Weston, Nils Rackelmann, Michael Podeschwa, Petra Arndt, Klaus Wirth, Heinz Goegelein, Olaf Ritzeler, Volker Kraft, Patrice Bellevergue, Gary McCort
-
Publication number: 20140349986Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula I and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.Type: ApplicationFiled: July 24, 2014Publication date: November 27, 2014Applicant: SANOFIInventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann
-
Patent number: 8822449Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.Type: GrantFiled: August 25, 2009Date of Patent: September 2, 2014Assignee: SanofiInventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann
-
Publication number: 20140243292Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 11, 2014Publication date: August 28, 2014Applicant: SanofiInventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Michael PODESCHWA, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER, Volker KRAFT, Patrice BELLEVERGUE, Gary McCORT
-
Publication number: 20130065859Abstract: The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: September 12, 2011Publication date: March 14, 2013Applicant: SANOFIInventors: Werngard CZECHTIZKY, John WESTON, Nils RACKELMANN, Michael PODESCHWA, Petra ARNDT, Klaus WIRTH, Heinz GOEGELEIN, Olaf RITZELER, Volker KRAFT, Patrice BELLEVERGUE, Gary MCCORT
-
Publication number: 20110201590Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.Type: ApplicationFiled: August 25, 2009Publication date: August 18, 2011Applicant: SANOFI-AVENTISInventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann
-
Patent number: 7879563Abstract: The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a medicament for the treatment of a carnitine transporter deficiency, to methods of diagnosis of a carnitine transporter deficiency, to the use of a protein for the manufacture of an antibody reacting with a carnitine transporter, to an oligonucleotide and to methods of treatment of a carnitine transporter deficiency.Type: GrantFiled: August 13, 2005Date of Patent: February 1, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Petra Arndt, Daniel Margerie, Bodo Brunner
-
Publication number: 20090184006Abstract: The present invention refers to a method for determining the activity of the organic cation transporter (OCT), a method for determining the activity of or identifying a chemical compound that modulates the activity of OCT with the help of a cell free electrophysiological sensor chip containing a solid-supported sensor electrode and a lipid layer containing the OCT located in the immediate spatial vicinity to the sensor electrode, whereas the sensor electrode is electrically insulated relative to the solutions used and to the lipid layer, as well as to the sensor chip itself and a kit containing same.Type: ApplicationFiled: January 22, 2007Publication date: July 23, 2009Applicant: SANOFI-AVENTISInventors: Henning Vollert, Sven Geibel, Bela Kelety, Klaus Fendler, Petra Arndt, Olga Gaiko, Ingo Janausch
-
Publication number: 20080132447Abstract: The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a medicament for the treatment of a carnitine transporter deficiency, to methods of diagnosis of a carnitine transporter deficiency, to the use of a protein for the manufacture of an antibody reacting with a carnitine transporter, to an oligonucleotide and to methods of treatment of a carnitine transporter deficiency.Type: ApplicationFiled: August 13, 2005Publication date: June 5, 2008Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Petra Arndt, Daniel Margerie, Bodo Brunner
-
Publication number: 20050112701Abstract: The present invention refers to a test system for the identification of a ligand for angiotension receptor like-1 (APJ receptor) comprising an APJ receptor or a functional variant thereof and a G?q or a G?l protein or a hybrid protein which is assembled from portions of different G proteins like G?q or G?l proteins, a method of screening an APJ receptor ligand using the test system, a method for producing a medicament, a method for diagnosis and prognosis of a heart disease and a kit usable for detection or prognosis of a heart disease.Type: ApplicationFiled: August 31, 2004Publication date: May 26, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Petra Arndt, Daniel Margerie, Goetz Muench, Martin Ungerer